Physician connectivity reduces workload

In a recent Managed Healthcare Executive K-Cast video series, R. Robert Auger, M.D., a psychiatrist and sleep specialist at the Mayo Clinic in Rochester, Minnesota, spoke about the diagnosis and treatment of narcolepsy and idiopathic hypersomnia. This is a written recap of that series.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting factors.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to lifestyle changes and long-term effectiveness—to help patients and providers separate hype from reality.

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their effects on various other conditions, such as sleep apnea, substance use disorder and Alzheimer’s disease, according to panelists participating in a keynote session of the Academy of Managed Care Pharmacy annual meeting today in Houston.